Product Description
an adeno-associated virus serotype 8 (AAV8)-based FIX Padua gene therapy
Mechanisms of Action: Gene Therapy,FIX
Novel Mechanism: No
Modality: Gene Therapy
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Hemophilia A|Hemophilia B
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
AskBio009-101 | P2 |
Active, not recruiting |
Hemophilia B|Hemophilia A |
2030-01-17 |
24% |